Clinical

Addressing Disparities Starts With Engaging the Community

September 24th 2021, 3:45pm

Article

In the opening sessions at the Patient-Centered Oncology Care® conference, held September 23-24 both virtually and in Nashville, Tennessee, speakers focused on addressing disparities by getting involved and engaged with the community.

Report: 2 Patients With RA Experienced Peripheral Neuropathy on JAK Inhibitor

September 23rd 2021, 9:05pm

Article

The reports suggest patients with rheumatoid arthritis (RA) could experience secondary neurological adverse events, though the side effect appears to be rare.

IV Belimumab for SLE Reduces Flare-Ups, Oral Corticosteroid Use

September 23rd 2021, 8:10pm

Article

Intravenous belimumab had benefits, but also resulted in more health care utilization due to the nature of its administration.

Single Blood Sample Test Could Improve Efficiency of T1D Progression Screening

September 23rd 2021, 6:00pm

Article

A team of Australian researchers created and validated a model that may boost efficiency of type 1 diabetes (T1D) progression screening.

MRD Monitoring Useful Across Risk Groups in ALL

September 23rd 2021, 3:15pm

Article

In a recent paper, researchers outlined the utility of minimal residual disease (MRD) among patient with acute lymphoblastic leukemia (ALL) and how its monitoring at specific timepoints has proven useful for stratifying patients and helping to ensure appropriate treatment decisionsMRD

Better Knowledge Needed of Unmet Needs of Cancer Survivors

September 23rd 2021, 1:30pm

Article

Two posters presented at the European Society of Medical Oncology highlighted the unmet needs of cancer survivors.

Ruxolitinib Cream Approved for Short-term Treatment of Atopic Dermatitis

September 22nd 2021, 9:50pm

Article

Ruxolitinib cream, to be sold under the name Opzelura, is the first topical Janus kinase inhibitor cream for the treatment of atopic dermatitis.

FDA Approves Ruxolitinib for Chronic GVHD

September 22nd 2021, 6:30pm

Article

Chronic graft-vs-host disease (GVHD) is a condition that can occur after an allogeneic stem cell transplant in which the donated cells initiate an immune response and attack the transplant recipient’s organs.

COVID-19 Symptoms Can Differentiate Respiratory Diseases, Study Says

September 21st 2021, 4:50pm

Article

Among patients with COVID-19, chronic obstructive pulmonary disease and asthma were more prevalent than allergic rhinitis.

Encourage Further SGLT2 Inhibitor Treatment for Diabetes, Kidney Disease, Expert Says

September 20th 2021, 2:23pm

Article

New data from the CREDENCE trial shows that the sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin may reduce hyperkalemia risk in people with type 2 diabetes and chronic kidney disease who are using RAAS inhibitors.